Editas Medicine Presents Pre-Clinical Data from a Study of EDIT-301 with Sickle Patient Cells for the Potential Treatment of ...
CAMBRIDGE, Mass., June 12, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced results from a pre-clinical, proof-of-concept study of EDIT-301. EDIT-301 is being developed as a potentially best- …